Scientific Program - Friday Oct 31, 2008 -

	HALL A
08:15-08:30	Greetings I. Raz, Israel

08:30-10:00	Session 01 Diabetes – Goals and Treatment
Chairpersons:	A. Ametov, Russia A. De Leiva, Spain
08:30-09:00	Definition of progression of type 2 diabetes V.A. Fonseca, USA
09:00-09:30	Changing the treatment paradigm for type 2 diabetes S. Del Prato, Italy
09:30-10:00	Insulin therapy for type 2 diabetes J.H. de Vries, The Netherlands
10:30-12:30	Session 02 Diabetes Prevention
Chairpersons:	I. C. Conget, Spain I. Paiva, Portugal
10:30-11:30 Debate:	Non–pharmacologic vs pharmacologic intervention to prevent diabetes Pro: Pharmacologic treatment A. Garber, USA Con: Non-pharmacologic treatment J. Tuomilehto, Finland
11:30-12:30 Debate:	Early insulin treatment Pro: L. Meneghini, USA Con: J.L. Chiasson, Canada
13:15-14:15	Satellite Symposium PostMeal Glucose – from controversy to consensus Sponsored by LifeScan EMEA
Chairperson	A. Ceriello, UK
	Guidelines: Pro’s and Con’s Implementation L.A. Leiter, Canada What does this mean for therapy and therapy change? L. Monnier, France
14:15-16:15	Session 03 Glycemic Control
Chairpersons:	J.C. Daubresse, Belgium D. Mauricio, Spain M. Bastos, Portugal
14:15-15:15 Debate:	Target for glycemic control: Concentrating on glucose vs. HbA1c Glucose: L. Monnier, France HbA1c: M. Massi-Benedetti, Italy
15:15-16:15 Debate:	Self blood glucose monitoring (SBGM) vs. continuous glucose monitoring (CGM) SBGM: S. Raptis, Greece CGM: A. de Leiva, Spain
16:45-17:45	Session 04 The Endothel in Diabetes
Chairperson:	J.F. Ascaso Gimilo, Spain E. Rodrigues, Portugal
16:45-16:55	Accelerated preclinical carotid/femoral atherosclerosis in a group of young subjects with type 1 diabetes from a Mediterranean area M. Gimenez R. Gilabert I. Conget, Spain
16:55-17:05	Atherosclerotic plaque inflammation synchronize with inflammatory activity of visceral fat S. Kim, E. J. Kim, H.S. Seo, J. S. Yeo, J. O.Na, J. H. Park, C. U. Choi, H. E. Lim, J. W. Kim, S.W. Rha, C. G. Park, D. J. Oh, South Korea
17:05-17:15	The effects of rosiglitazone on atherosclerotic progression in type 2 diabetes M. Yee, A. Varghese, D. Pavitt, S. Dhanjil, I. Godsland, W. Richmond, D. Pennell, D. Johnston, UK
17:15-17:45	EASD guidelines: Debate and consensus E. Standl, Germany
	HALL B
10:30-12:30	Session 05 Hypertension in Diabetes
Chairpersons:	F. de Alvaro, USA A. Zanchetti, Italy
10:30-11:00	How to define pre-hypertension in diabetes / metabolic syndrome A.M. Heagerty, UK
11:00-11:30 Debate:	Treatment of pre-hypertension in diabetes / metabolic syndrome Pro: L.M. Ruilope, Spain Con: E. Grossman, Israel
11:30-12:00	Should 24h ABPM be done in every patient with diabetes? G. Parati, Italy
12:00-12:30 Debate:	Should we treat diabetic patients with white coat hypertension? Pro: G. Mancia, Italy Con: M. Bursztyn, Israel
14:15-16:15	Session 06 Hyperglycemia and CVD
Chairpersons:	N.D. Hancu, Romania G. Jermendy, Hungary
14:15-15:15 Debate:	Is there evidence that OHG reduces CV morbidity/mortality? Pro: S. Del Prato, Italy Con: I. Raz, Israel
15:00-16:00 Debate:	Shifting the disease management paradigm from glucose Pro: D. Tschope, Germany Con: M. Hanefeld, Germany
16:15-16:45	Session 23 Post Prandial Hyperglycemia
Chairpersons:	T. Herskovitz, Israel R. Lichiardopol, Romania
16:45-17:05	Exenatide versus insulin in the HEELA study M. Davies, UK
17:05-17:15	Effect of exenatide versus placebo on weight loss in subjects with type 2 diabetes participating in a lifestyle modification program L. Glass, L. Wolka, Y. Guo, Y. Qu
17:15-17:45	Accurate prediction of the risk of future type 2 diabetes: Do we need the OGTT M.A. Abdul-Ghani, USA
	HALL C
10:30-12:30	Session 07 Obesity and Diabetes
Chairpersons:	D. Dicker, Israel M. Petkova, Bulgaria
10:30-11:30 Debate:	Fat or fit – What is more important? Fat: H. Toplak, Austria Fit: V. Hainer, Czech Republic
11:30-12:30 Debate:	Obesity in the elderly diabetic patient-disease? Yes: N. Stern, Israel No: C. Tsigos, Germany
14:15-16:15	Session 08 Clinical Applications of Evidence-Based Medicine for Effectively Managing Type 2 Diabetes: Considerations for Incretin Therapies
Chairpersons:	J. A. Davidson, USA
14:15-14:25	Welcome and introduction J.A. Davidson, USA
14:25-14:50	Understanding the normal physiology of gut peptides and the pathophysiology of insulin and glucagon secretion in Type 2 diabetes J.A. Davidson, USA
14:50-15:15	Goals of treatment for type 2 diabetes: Beta cell preservation for glycaemic control P. Marchetti, Italy
15:15-15:40	Attainment of clinical goals with novel therapies T. Vilsboll, Denmark
15:40-16:05	Practical applications: A case-based discussion Panel
16:05-16:15	Questions and answers J.A. Davidson, USA
16:30-17:30	Keynote Lectures Approach to the Treatment of Morbid Obesity
16:30-17:00	The IDF Consensus Statement on Sleep Apnoea and Type 2 Diabetes E. Standl, Germany
17:00-17:30	The Swedish Obese Subject (SOS) - Treatment and prevention of diabetes and other cardiovascular risk factors in SOS D. Sjostrom, Sweden